Healthcare provider profile · identity verified

Wei Wang, MD

Internal Medicine · IRVINE, CA · NPI 1750743969

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	517	177
Losartan Potassium	Losartan Potassium	345	106
Amlodipine Besylate	Amlodipine Besylate	272	84
Levothyroxine Sodium	Levothyroxine Sodium	255	76
Metformin Hcl	Metformin Hcl	248	83
Tamsulosin Hcl	Tamsulosin Hcl	146	52
Lisinopril	Lisinopril	145	45
Rosuvastatin Calcium	Rosuvastatin Calcium	143	45
Ozempic	Semaglutide	117	22
Gabapentin	Gabapentin	105	46
Omeprazole	Omeprazole	105	45
Fluticasone Propionate	Fluticasone Propionate	94	49
Metoprolol Succinate	Metoprolol Succinate	88	31
Duloxetine Hcl	Duloxetine Hcl	84	33
Escitalopram Oxalate	Escitalopram Oxalate	84	31
Alendronate Sodium	Alendronate Sodium	80	28
Simvastatin	Simvastatin	80	25
Jardiance	Empagliflozin	75	25
Famotidine	Famotidine	72	22
Metformin Hcl Er	Metformin Hcl	58	20
Synthroid	Levothyroxine Sodium	58	14
Finasteride	Finasteride	57	21
Allopurinol	Allopurinol	56	16
Hydrochlorothiazide	Hydrochlorothiazide	49	18
Lovastatin	Lovastatin	49	15
Trazodone Hcl	Trazodone Hcl	48	17
Azelastine Hcl	Azelastine Hcl	46	19
Atenolol	Atenolol	42	12
Eliquis	Apixaban	42	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	42	17
Ezetimibe	Ezetimibe	40	16
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	40	14
Potassium Chloride	Potassium Chloride	38	12
Pravastatin Sodium	Pravastatin Sodium	37	12
Trulicity	Dulaglutide	36	suppressed
Mounjaro	Tirzepatide	35	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	34	17
Benazepril Hcl	Benazepril Hcl	34	11
Bupropion Xl	Bupropion Hcl	33	11
Metoprolol Tartrate	Metoprolol Tartrate	30	suppressed
Sertraline Hcl	Sertraline Hcl	28	11
Irbesartan	Irbesartan	27	suppressed
Terazosin Hcl	Terazosin Hcl	27	suppressed
Valsartan	Valsartan	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	suppressed
Carvedilol	Carvedilol	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	14
Zolpidem Tartrate	Zolpidem Tartrate	20	11
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	14
Nifedipine Er	Nifedipine	17	suppressed
Azithromycin	Azithromycin	16	16
Ipratropium Bromide	Ipratropium Bromide	16	suppressed
Nystatin	Nystatin	15	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Linzess	Linaclotide	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Prednisone	Prednisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error